Wedbush downgraded shares of Ikena Oncology (NASDAQ:IKNA – Free Report) from an outperform rating to a neutral rating in a research report sent to investors on Wednesday morning, MarketBeat reports. The brokerage currently has $2.00 target price on the stock, down from their previous target price of $8.00. Wedbush also issued estimates for Ikena Oncology’s […]